Global Radiopharmaceuticals Market to Reach USD 25,884.6 Million by 2035 at 10.84% CAGR: Vectomat Insights
Vectomat Insights releases a 10-year forecast on the Global Radiopharmaceuticals Market, detailing how Lu-177 radioligand therapies are driving a 15.44% annual surge to overtake diagnostics by 2029, led by North America.
ST. CATHARINES, Ontario — November 13, 2026 — Vectomat Insights has published a comprehensive market research study projecting the global radiopharmaceuticals market to grow from USD 9,248.6 million in 2025 to USD 25,884.6 million by 2035, expanding at a 10.84% compound annual growth rate (CAGR).
While diagnostic radiopharmaceuticals account for 57.0% of 2025 revenue (USD 5,272.5 million) due to routine Technetium-99m and Fluorine-18 imaging scans, therapeutic agents represent the fastest-growing product segment. Driven by expanded FDA approvals for targeted radioligand therapies such as Novartis's Pluvicto, therapeutic radiopharmaceuticals are compounding at 15.44% annually and are projected to reach USD 16,716.9 million by 2035, overtaking diagnostics in market value by 2029.
From a regional perspective, North America leads global demand with a 40.3% market share in 2025 (USD 3,727.2 million), supported by U.S. Medicare reimbursement reforms for high-cost diagnostic tracers. Europe follows with 25.9%, while Asia-Pacific (22.7%) is the fastest-growing geographic region through 2035, led by South Korea's 13.0% CAGR.
The global competitive landscape is also undergoing major consolidation, highlighted by Curium's agreed merger with Lantheus Holdings (valued up to USD 8 billion) and Telix Pharmaceuticals' acquisition of ITM Isotope Technologies Munich (USD 1.65 billion upfront) to secure vertical isotope supply.
To preview key data tables and request a free sample of the 300-page report covering 35 countries and 15 company profiles, visit: https://www.vectomatinsights.com/report/radiopharmaceuticals-market
To select a license and purchase the full report, visit: https://www.vectomatinsights.com/checkout?report=radiopharmaceuticals-market&licence=single
About Vectomat Insights
Vectomat Insights is an independent market research firm providing analyst-validated intelligence across healthcare and life sciences. Sized bottom-up and validated top-down through an audited 16-step process, our reports deliver 10-year forecasts, country-level breakdowns, and competitive insights for strategic decision-makers.
While diagnostic radiopharmaceuticals account for 57.0% of 2025 revenue (USD 5,272.5 million) due to routine Technetium-99m and Fluorine-18 imaging scans, therapeutic agents represent the fastest-growing product segment. Driven by expanded FDA approvals for targeted radioligand therapies such as Novartis's Pluvicto, therapeutic radiopharmaceuticals are compounding at 15.44% annually and are projected to reach USD 16,716.9 million by 2035, overtaking diagnostics in market value by 2029.
From a regional perspective, North America leads global demand with a 40.3% market share in 2025 (USD 3,727.2 million), supported by U.S. Medicare reimbursement reforms for high-cost diagnostic tracers. Europe follows with 25.9%, while Asia-Pacific (22.7%) is the fastest-growing geographic region through 2035, led by South Korea's 13.0% CAGR.
The global competitive landscape is also undergoing major consolidation, highlighted by Curium's agreed merger with Lantheus Holdings (valued up to USD 8 billion) and Telix Pharmaceuticals' acquisition of ITM Isotope Technologies Munich (USD 1.65 billion upfront) to secure vertical isotope supply.
To preview key data tables and request a free sample of the 300-page report covering 35 countries and 15 company profiles, visit: https://www.vectomatinsights.com/report/radiopharmaceuticals-market
To select a license and purchase the full report, visit: https://www.vectomatinsights.com/checkout?report=radiopharmaceuticals-market&licence=single
About Vectomat Insights
Vectomat Insights is an independent market research firm providing analyst-validated intelligence across healthcare and life sciences. Sized bottom-up and validated top-down through an audited 16-step process, our reports deliver 10-year forecasts, country-level breakdowns, and competitive insights for strategic decision-makers.
- Contact Email
- [email protected]
- Issued By
- Vectomat Insights
- Website
- Vectomat Insights
- Phone
- +1 416-876-0312
- Business Address
- 6 ½ Smythe Street
St. Catharines, ON L2P 2G8 - Country
- Canada
- Categories
- Health · Medical · Pharma
- Last Updated
- November 13, 2026